antibodies
(4)
Abcam Turned the Antibody Catalog Into a Quality-Control Machine
The Cambridge company began with one postdoc’s bad antibody problem. Twenty-eight years later, its real product is not merely a vial - it is the confidence that a costly experiment will not have to be run twice.
Ability Biotherapeutics
Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.
Angèle Maki
Angèle Maki, PhD, is a biopharmaceutical business development executive with more than 20 years of deal-making across emerging biotechs and global pharma. In December 2025 she became the first Chief Business Officer of Ability Biotherapeutics, a Montreal-based company building logic-gated antibodies with its generative-AI platform AbiLeap. A Stanford-trained biological chemist who started at the University of Winnipeg, she has held senior roles at Medarex, Bristol Myers Squibb, Genentech, 23andMe, Merck, Eli Lilly, ReCode Therapeutics and Callio Therapeutics, and chairs the non-profit Canadian Entrepreneurs in Life Sciences.
Mark Gaffney
Mark Gaffney is the Chief Executive Officer and Board member of Calluna Pharma, an Oslo-based clinical-stage biopharma chasing inflammatory and fibrotic disease by tuning the body's innate immune system. A mechanical engineer turned lawyer turned dealmaker, he spent two decades building and selling biotechs - Oxular went to Regeneron, Vedere Bio to Novartis - before taking the helm of a company born from the merger of Oxitope Pharma and Arxx Therapeutics and freshly backed by a 75 million euro Series A.